Natera Revenue and Competitors

Location

$404.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Natera's estimated annual revenue is currently $564.8M per year.(i)
  • Natera's estimated revenue per employee is $145,878
  • Natera's total funding is $404.1M.
  • Natera's current valuation is $6.4B. (January 2022)

Employee Data

  • Natera has 3872 Employees.(i)
  • Natera grew their employee count by 6% last year.

Natera's People

NameTitleEmail/Phone
1
Co-FounderReveal Email/Phone
2
Chief Compliance & Privacy OfficerReveal Email/Phone
3
Chief Information Security Officer (CISO)Reveal Email/Phone
4
Global VP, BiopharmaReveal Email/Phone
5
Chief Accounting OfficerReveal Email/Phone
6
CEOReveal Email/Phone
7
VPReveal Email/Phone
8
VP, Patient ServicesReveal Email/Phone
9
VP Lab AffairsReveal Email/Phone
10
VP Research And Development, OncologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$434.8M1865-14%$2B$2.7B
#2
$76.6M669-7%$574.9MN/A
#3
$343.9M31767%$550M$7.9B
#4
$218.4M299-63%$791M$974.7M
#5
$37.9M26529%N/AN/A
#6
$31.5M2031%N/AN/A
Add Company

What Is Natera?

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

keywords:Biotechnology

$404.1M

Total Funding

3872

Number of Employees

$564.8M

Revenue (est)

6%

Employee Growth %

$6.4B

Valuation

N/A

Accelerator

Natera News

2022-04-20 - Natera Announces Definitive Study to Evaluate the Clinical ...

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease...

2022-04-19 - Bragar Eagel & Squire, PC Is Investigating Natera, Mullen ...

Bragar Eagel & Squire, P.C. Is Investigating Natera, Mullen, Arqit, and Netflix and Encourages Investors to Contact the Firm.

2022-03-22 - Natera Listed as One of World's Most Innovative Health ...

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized...

2021-10-28 - Natera Announces Third Quarter 2021 Earnings Conference Call

AUSTIN, Texas, Oct. 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2021, after the market close on November 4, 2021. Natera will ...

2021-10-18 - Natera : Expands Organ Health Business With Commercial Launch of the Prospera™ Lung Transplant Assessment Test

AUSTIN, Texas, Oct. 18, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, announced the launch and availability of its Prospera donor-derived cfDNA (dd-cfDNA) transplant assessment test for lung transplant recipient ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$523.8M46853%N/A
#2
$2130M6770N/AN/A
#3
$1521.4M77625%N/A
#4
$2260M79135%N/A
#5
$2260M79135%N/A